Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14M | $5.79M | $5.56M | $5.20M | $6.69M | $7.20M | $18.9M | $5.34M | $5.42M | $5.31M |
| Revenue growth | — | 12.7% | -3.9% | -6.5% | 28.7% | 7.6% | 162.1% | -71.7% | 1.4% | -1.9% |
| Gross profit | $1.52M | $2.02M | $1.75M | $1.29M | $1.78M | $366K | $2.98M | $446K | $611K | $498K |
| Gross margin | 29.7% | 34.9% | 31.5% | 24.8% | 26.6% | 5.1% | 15.8% | 8.4% | 11.3% | 9.4% |
| Operating income | -$827K | -$955K | -$1.48M | -$2.41M | -$2.40M | -$7.50M | -$4.53M | -$7.22M | -$6.37M | -$5.14M |
| Operating margin | -16.1% | -16.5% | -26.6% | -46.4% | -35.9% | -104.2% | -24.0% | -135.3% | -117.6% | -96.7% |
| Net income | -$1.50M | -$909K | -$1.47M | -$2.39M | -$2.34M | -$7.45M | -$4.53M | -$7.14M | -$5.98M | -$4.97M |
| Net margin | -29.2% | -15.7% | -26.3% | -46.0% | -34.9% | -103.4% | -24.0% | -133.7% | -110.4% | -93.6% |
| EPS (diluted) | -$0.20 | -$0.11 | -$0.17 | -$0.26 | -$0.23 | -$0.62 | -$0.36 | -$0.50 | -$2.84 | -$2.16 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$209K | -$723K | -$1.17M | -$2.24M | -$4.30M | -$5.25M | -$479K | -$5.47M | -$5.36M | -$3.84M |
| Capital expenditures | $91.6K | $96.1K | $130K | $101K | $33.6K | $136K | $57.0K | $64.0K | $51.0K | — |
| Free cash flow | -$300K | -$819K | -$1.30M | -$2.35M | -$4.33M | -$5.39M | -$536K | -$5.54M | -$5.41M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.89M | $1.23M | $1.20M | $687K | $8.64M | $4.20M | $5.92M | $9.72M | $4.17M | $2.40M |
| Total assets | $5.73M | $5.02M | $5.22M | $5.25M | $17.3M | $11.8M | $11.4M | $14.5M | $9.25M | $5.95M |
| Total liabilities | — | — | — | $1.26M | $3.05M | $2.59M | $3.05M | $2.73M | $2.66M | $1.84M |
| Shareholders' equity | $5.22M | $4.49M | $4.33M | $3.98M | $14.2M | $9.23M | $8.32M | $11.7M | $6.59M | $4.11M |
| Retained earnings | -$14.8M | -$15.7M | -$17.2M | -$19.6M | -$21.9M | -$30.5M | -$35.1M | -$42.2M | -$48.2M | -$53.2M |
| Shares (wtd avg diluted) | 7.63M | 8.33M | 8.57M | 9.21M | 10.2M | 11.9M | 12.7M | 14.2M | 2.10M | 2.30M |
Every figure is extracted from BIOMERICA INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.